Biopharmaceutical News and Research

RSS
Cangene third-quarter revenues decline 39% to $41.1M

Cangene third-quarter revenues decline 39% to $41.1M

15 Jun 2010
ICON, PAREXEL to provide global support for execution of Bristol-Myers Squibb's clinical studies

ICON, PAREXEL to provide global support for execution of Bristol-Myers Squibb's clinical studies

From Parexel 15 Jun 2010
PAREXEL, Bristol-Myers Squibb establish strategic partnership in clinical development

PAREXEL, Bristol-Myers Squibb establish strategic partnership in clinical development

From Parexel 14 Jun 2010
New Brunswick Scientific, Pall partner to develop new disposable bioreactor systems

New Brunswick Scientific, Pall partner to develop new disposable bioreactor systems

From Pall Corporation 14 Jun 2010
MP Biomedicals to acquire ICPbio International

MP Biomedicals to acquire ICPbio International

From MP Biomedicals, LLC 14 Jun 2010
Esperion, Cleveland Clinic collaborate to research new HDL therapies for cardiovascular disease

Esperion, Cleveland Clinic collaborate to research new HDL therapies for cardiovascular disease

14 Jun 2010
Oragenics awarded additional $500,000 to further development of MU 1140, DPOLT antibiotics platform

Oragenics awarded additional $500,000 to further development of MU 1140, DPOLT antibiotics platform

14 Jun 2010
Telormedix initiates Phase I/II clinical study of TMX-101 for treating NMIBC

Telormedix initiates Phase I/II clinical study of TMX-101 for treating NMIBC

14 Jun 2010
UBC earns high ratings in 2010 late phase market dynamics survey

UBC earns high ratings in 2010 late phase market dynamics survey

14 Jun 2010
TF12 antibody targets EGP-1 expressed in epithelial cancer: Immunomedics

TF12 antibody targets EGP-1 expressed in epithelial cancer: Immunomedics

14 Jun 2010
CAMD releases first combined clinical trial data on neuro-degenerative diseases

CAMD releases first combined clinical trial data on neuro-degenerative diseases

14 Jun 2010
NeoPharm first-quarter net loss decreases to $1.4 million

NeoPharm first-quarter net loss decreases to $1.4 million

11 Jun 2010
AVEO Pharmaceuticals presents tivozanib’s Phase 2 trial data at ASCO meeting

AVEO Pharmaceuticals presents tivozanib’s Phase 2 trial data at ASCO meeting

11 Jun 2010
Perceptive Informatics releases new web-based version of DataLabs Designer module

Perceptive Informatics releases new web-based version of DataLabs Designer module

11 Jun 2010
ViroStatics, Vichem Chemie partner to discover new AV-HALT drugs

ViroStatics, Vichem Chemie partner to discover new AV-HALT drugs

11 Jun 2010
Investment report on Novavax

Investment report on Novavax

11 Jun 2010
sanofi pasteur congratulates Canadian Public Health Association for 100 years of leadership and service

sanofi pasteur congratulates Canadian Public Health Association for 100 years of leadership and service

11 Jun 2010
Innovaro facilitates protein transduction technology licensing between Trojan Technologies, Trojantec

Innovaro facilitates protein transduction technology licensing between Trojan Technologies, Trojantec

11 Jun 2010
Idenix initiates IDX320 proof-of-concept study for HCV infection

Idenix initiates IDX320 proof-of-concept study for HCV infection

10 Jun 2010
PAREXEL experts to present on biopharmaceutical industry issues at 46th DIA

PAREXEL experts to present on biopharmaceutical industry issues at 46th DIA

From Parexel 10 Jun 2010

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback